5 Key Takeaways

• 1

  Drug development has evolved through distinct eras, from small molecules to biologics, culminating in advanced cell and gene therapies.

• 2

  Manufacturing challenges have become the primary hurdle in developing cell and gene therapies, shifting focus from drug discovery to production.

• 3

  Cost remains a significant barrier in advanced therapies, particularly for rare diseases, necessitating strategies to reduce development and manufacturing expenses.

• 4

  Funding for cell and gene therapy companies has become increasingly difficult to secure, mirroring trends seen during past economic downturns.

• 5

  The consultancy emphasizes the importance of the 'five Ps'—People, Patent, Product, Profit, and PR—in assessing the viability of companies in the sector.